Events Search and Views Navigation
Despite expanding treatment options for relapsed/refractory multiple myeloma (MM), hematology/oncology teams face persistent barriers to the delivery of quality care across MM patient populations. Join our expert faculty for this live webinar as they share real-world insights and lessons learned from an MM quality initiative conducted within two large oncology health systems.Find out more »
The North America IMS Educational Workshop scheduled to occur in Miami, Florida will now be offered in a virtual format on November 6-7, 2020. While advance registration is required, access to the above IMS Educational Workshops will be made available on a complimentary basis for all IMS members. The registration rate for non-members will be $100.00. The IMS would like to thank all of our members, faculty, attendees, and supporters for their cooperation and understanding during this time. Despite this…Find out more »
This educational series is designed to provide insights and guidance on the critical and challenging issues in multiple myeloma. Our approach is to examine the entire spectrum from bench to bedside by critically analyzing and challenging current practice.Find out more »
In this live webcast, expert faculty will discuss the best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient's perspective on treatment options.Learners will also get a look ahead at emerging therapeutic strategies and clinical trials that may soon change practice.Find out more »
Within a very short period of time, there has been a tremendous advance in development of cellular immunotherapies in multiple myeloma (MM). As we have observed during our event last year, a number of groups have presented their data on CAR T-cell therapy in MM. Although the studies are currently small in size, they are accruing patients very quickly, both in the United States and globally.
These developments have highlighted the need for a focused discussion about the state-of-the-art in immune and cellular therapies. With this in mind, the International Myeloma Society (IMS) is organizing the 2nd Immune Effector Cell Therapy in Multiple Myeloma Workshop. This two-day meeting will review CAR-T clinical data and promising preclinical leads, gain consensus on issues in management of toxicity, and discuss ongoing and future clinical trials. This year we are also including a session on T cell-engaging bispecific antibody-based approaches.Find out more »